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ABSTRACT 
Background: Prostate cancer is associated with increased cardiovascular risk.Atherogenic lipoprotein profile is an 
important risk factor for cardiovascular diseases. The aim of this study is to determine the atherogenic lipid markers and 
testosterone levels in Nigerian men with prostate cancer (PCa) and benign prostate hyperplasia (BPH) to evaluate their 
usefulness for predicting cardiovascular events in patients with prostate disorders. Methods: Study subjects consisted of 
40 PCa patients, 32 BPH patients and 32 apparently healthy controls. Serum lipid profile, prostate specific antigen (PSA) 
and testosterone levels were determined using standard procedures. Atherogenic index of plasma (AIP) was calculated as 
log (triacylglycerol/high density lipoprotein-cholesterol). Results: The results from the study indicate that PCa and BPH 
subjects had significantly higher (p < 0.05) levels of total cholesterol (TC), low density lipoprotein- cholesterol (LDL-c), 
very low density lipoprotein-cholesterol (VLDL-c),Triacylglycerol (TAG) and AIP while high density lipoprotein-
cholesterol (HDL-c) was significantly lower (p < 0.05) compared to the controls. However, PCa patients had significantly 
lower (p < 0.05) HDL-c and testosterone levels but significantly higher (p < 0.05) AIP levels compared to BPH patients. In 
PCa patients AIP, TC, and LDL-c showed significant positive correlations with PSA while a significant negative 
correlation was observed between HDL-c .and PSA. In BPH patients a significant positive correlation was observed 
between total testosterone and PSA. Conclusions: Prostate disorders are associated with altered lipid profile and 
atherogenic lipid markers. AIP may be useful in predicting the risk of cardiovascular diseases in Nigerian men with PCa 
and BPH.  
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Introduction 
 
 
The morbidity and mortality of prostate cancer is 
rapidly increasing in the past decades especially in the 
developing countries like Nigeria. The reasons for this 
increase have not been fully elucidated. Several 
epidemiological studies have investigated the relation 
between prostate cancer incidence and a broad range of 
endogenous and exogenous factors, including lipids 
levels [1] but data on the prostate cancer-lipids 
relationship are inconsistent. Lipids comprise diverse 
classes of molecules with critical functions in cellular 
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energy storage, structure, and signaling. They also 
might be associated with cancers because they play a 
key role in the maintenance of cell integrity [2]. 
Cholesterol and triglycerides which are important lipid 
constituents of cell carry out several vital physiological 
functions such as the maintenance of the structure and 
functional integrity of all biological membranes. 
Cholesterol is also involved in other biological 
functions including cell growth and division, the 
activity of membrane bound enzymes and stabilizing 
the DNA double helix. In plasma, triglycerides and 
cholesterol are packaged into lipoproteins which are 
then taken up and degraded by the cells. In the prostate 
gland, lipids promote the cellular proliferation, 
contractility and overall enlargement of the prostate 
and thus represent a potential risk factor for BPH and 
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prostate cancer [3]. The prostate is a cholesterol-rich 
tissue; therefore elevated serum cholesterol may result 
in the accumulation of cholesterol in the cell membrane 
forming large lipid rafts [4]. These lipid rafts have been 
shown to have pro-carcinogenic cell signalling effects. 
Dyslipidemia has a complex pathophysiology 
consisting of various genetic, lifestyle, and 
environmental factors. It has many adverse health 
impacts, notably in the development of chronic non-
communicable diseases. Altered lipid metabolism is 
increasingly recognized as a feature of cancer cells and 
blood cholesterol undergoes early and significant 
changes in some malignant diseases [5]. Low-density 
lipoprotein (LDL) can build up in the walls of the 
arteries that feed the heart and brain and form plaque—
a thick, hard deposit that can clog those arteries, a 
condition known as atherosclerosis. Conversely, 
elevated levels of high-density lipoprotein (HDL) have 
been shown to prevent heart disease, while low HDL 
level increases the risk of heart attack and stroke [6].  
In vitro reduction of cholesterol has been shown to 
induce apoptosis in prostate cancer [7], while treatment 
with statins leads to about a 50% reduction in the first 
cardiovascular event [8]. Elevated triglycerides may 
increase prostate cancer risk through lipoprotein 
signalling pathways. Hypertriglyceridemia results in 
the accrual of very low-density lipoproteins, 
chylomicrons, which are hydrolyzed, producing 
remnant lipoproteins. Lipoprotein remnants result in 
activation of Akt signal transduction, and mitogen-
activated protein kinases, which increase prostate 
cancer cell proliferation. A high triacylglycerol level 
combined with a low HDL or high LDL can speed up 
the process of plaque formation in the arteries. Several 
studies have shown significant associations between 
high TAG levels and an increased risk of malignant 
tumours [2]. The potential mechanisms for the 
association between hypertriglyceridemia and cancer 
development include insulin resistance, infection, 
inflammation, and oxidative stress [6] [1].  
Atherogenic lipoprotein profile of plasma is an 
important risk factor for cardiovascular disease which 
is characterized by a high ratio of LDL-cholesterol to 
HDL-cholesterol [9].  
Atherogenic index of plasma (AIP) is the new marker 
of atherogenicity, given that AIP is related directly to 
the atherosclerosis risk. AIP is the ratio calculated as 
log (TAG/HDL- cholesterol) [10]. Existence of 
hypertriglyceridemia has been shown to increase the 
activity of hepatic lipase resulting in increased HDL-
cholesterol catabolism. Susanti et al. [11] reported that 
each degradation of 1mg HDL- cholesterol will 
correlates with 2% increase in the risk coronary heart 
disease.Testosterone, a steroid hormone derived from 
cholesterol, occurs more abundantly in circulation 
among men. During the aging process, testosterone 
levels diminish gradually. This characteristic hormonal 
change of male aging is of interest because lower 
testosterone concentrations are commonly associated 
with a number of clinical conditions [12]. Evidence 
suggests that serum testosterone levels in men are 
negatively associated with LDL and triglycerides and 
positively related to HDL-cholesterol levels indicating 
that low serum total testosterone is associated with an 
unfavorable lipid profile [13]. Some studies now 
demonstrate that elevated risk is associated with low 
androgen states especially among men who have 
undergone androgen-deprivation therapy (ADT) for 
treatment of prostate cancer [14]. Interventional studies 
have also shown that testosterone replacement in 
hypogonadal men results in a significant decrease in 
total cholesterol, LDL cholesterol and triglycerides 
while serum HDL levels show an insignificant decrease 
[15].Despite widespread perception of a relationship 
between testosterone and prostate cancer risk, the 
majority of epidemiological studies are inconclusive. 
The role of testosterone in modifying lipoprotein 
function and cardiovascular risk in men remains highly 
uncertain and constitutes an intriguing area of emergent 
research. Also there is a paucity of studies on the 
usefulness of AIP as a tool for identification of the risk 
of cardiovascular disease in patients with prostate 
disorders. The aim of the present study is to determine 
the atherogenic lipid markers and testosterone levels in 
Nigerian men with BPH and prostate cancer in order to 
evaluate their usefulness for predicting cardiovascular 
events. Thus, the lipid profile analysis in patients with 
prostate disorders presents itself as a promising tool 
especially because of its potential contribution to a 
better management of prostate conditions since the 
majority of the cardiovascular signs and symptoms are 
associated with dyslipidemia. 
 
Materials and methods  
 
One hundred and four (104) human subjects within the 
aged 53-85years (average 69 years) participated in this 
study. They were sub-divided into groups A, B and C. 
Group A were 32 apparently healthy subjects who 
served as the control subjects. They were age and sex- 
matched with the test subjects (B and C). Group B 
were made up of 32 patients diagnosed with benign 
prostate hyperplasia (BPH) and were attending urology 
clinics at the University of Nigeria Teaching Hospital 
Ituku/Ozalla, Enugu. Group C consisted of 40 prostate 
cancer patients who were either attending the urology 
clinic or were admitted at the wards at the University 
of Nigeria Teaching Hospital Ituku/Ozalla, Enugu  and 
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whose clinical records were well known from their 
medical history. The patients were newly diagnosed 
cases, although some of them have advanced prostate 
cancer. They were not known to have any other acute 
or chronic medical problems and were therefore not yet 
on any known medication or supplements. They were 
yet to be placed on any form of therapy at the time of 
blood collection.   
Exclusion criteria: For all the groups, the subjects 
were non diabetics, non smokers and non alcoholics 
and were not taking any medication that may interfere 
with the parameters.  
 Inclusion criteria: In each case, BPH or Prostate 
cancer was medically and histologically diagnosed in 
Chemical Pathology and Histopathology Departments 
of the University of Nigeria Teaching Hospital, 
Ituku/Ozalla, Enugu. 
Information about smoking status and other health and 
work-related issues were obtained by a questionnaire 
and also from their hospital folders. The study was 
conducted at the Urology Clinic, Wards, Haematology 
and Chemical Pathology Departments of the University 
of Nigeria Teaching Hospital (UNTH), Ituku/Ozalla, 
Enugu.  
The study was carried out on the subjects after 
informed consent was obtained from each of them 
while the approval for the study was given by the 
Ethical Clearance Committee of UNTH, Ituku /Ozalla.  
Sample collection and treatment 
Blood samples were collected from the subjects after 
an overnight fast (12hrs) and distributed into plain 
centrifuge tubes for determination of total prostate 
specific antigen (PSA), testosterone, total cholesterol, 
HDL-cholesterol and triacylglycerols. The samples 
were allowed to clot, spun at 4,000 rpm for 10 minutes 
in a Jenlab bench centrifuge, model 80-2 and the sera 
pipetted into serum bottles and analyzed.Serum total 
PSA concentration was estimated with ELISA kits 
produced by Diagnostic Automation / Cortez 
Diagnostics Inc. (Calabasas, California, USA) as 
described by. Serum total testosterone concentration 
was estimated with ELISA kits produced by DiaMetra 
(SEGRATE, M.I. Italy) by the method of [17].Total 
cholesterol concentration was determined as described 
by [18] using QCA commercial kits produced by 
BIOLABO (S.A. France). Triacylglycerol was 
estimated by the method of [19] using glycerol 
phosphate oxidase/peroxidase kits produced by Linear 
Chemicals, (Barcelona, Spain). HDL cholesterol was 
estimated by enzymatic colorimetric method of [20] 
with QCA reagent kits by BIOLABO (S.A. France). 
Serum LDL-cholesterol and VLDL were calculated 
using Friedewald’s formula which is LDL-C = TC–
(TG/2.2 + HDL-C) and VLDL = TG/2.2. [21-22]. The 
AIP was calculated as log (TG/HDL-c) using the 
Czech online calculator of atherogenic risk [10]. 
Data analysis 
All statistical analyses were carried out using the 
statistical package program version SSPS 17.0 (SPSS, 
Inc., Chicago, IL, USA). Results were expressed as 
mean ± standard deviation. Level of significance 
between mean values of control and test groups was 
calculated and defined as p ˂ 0.05.Correlation 
coefficient at 95% or 99% confidence interval between 
the parameters was also calculated. 
 
Results 
 
Table 1: Mean levels of PSA and testosterone in the BPH, PCa and control groups (A, B and C) 
 
Groups PSA (ng/ml) Testosterone (ng/ml) 
A 
n= 32 
2.8 ±2.6 4.6±1.5 
B  
n= 32 
6.1±2.0a 4.1±1.4 
C 
n= 40 
34.5±26.8ab 1.7±1.1ab 
 
KEY: A = Normal control group B = BPH group   C = PCa group   n = no of subjects,     
 a = p < 0.05 when compared with group A.  ab = p < 0.05 when compared with groups A& B 
Table 1 shows the mean levels of PSA in the BPH, PCa 
and control groups (A, B and C). The table indicates 
that relative to the mean level of PSA in both BPH 
(6.1±2.0ng/ml) and the control (2.8 ±2.8ng/ml) groups, 
that of PCa group (34.5±26.8 ng/ml) was significantly 
 Asian Pac. J. Health Sci., 2015; 2(2): 48-55                                             e-ISSN: 2349-0659,   p-ISSN: 2350-0964                         
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________
Duru et al     ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2015; 2(2): 48-55 
www.apjhs.com      51 
 
higher (p < 0.05) and when the values for BPH and 
control groups were compared, that of BPH was also 
significantly higher (p < 0.05). However, when the test 
subjects were compared, the BPH group had 
significantly lower (p < 0.05) values than the PCa 
group.  
The mean testosterone level in PCa group (1.7±1.1) 
was significantly decreased (p < 0.05) compared to 
those of BPH (4.1±1.4) and the control (4.6±1.5) 
groups but no significant difference (p > 0.05) was 
observed between BPH and the control groups.  
 
Table 2:  The mean concentrations of total cholesterol, HDL-cholesterol, LDL-cholesterol, VLDL-cholesterol, 
triacylglycerol and AIP in the different groups. 
 
 
Groups 
 
 
Total-c. 
(mmol/L) 
 
HDL-c  
(mmol/L) 
 
LDL-c. 
(mmol/L) 
 
VLDL-c. 
(mmol/L) 
 
T.G 
(mmol/L) 
 
AIP 
 A 
n= 32 
 
4.4± 0.9 
 
1.1±0.3 
 
3.1±0.8 
 
0.4±0.1 
 
0.8±0.2         
 
- 0.11 ± 0.21 
B  
n= 32 
5.7±1.3a 0.7±0.2a 
 
4.4±1.1a 0.6±0.3a 1.3±0.7a 0. 22 ± 0.24a 
C 
n= 40 
 
5.8±1.7a 
 
0.5±0.2ab 
 
4.6±1.8a 
 
0.7±0.5a 
 
1.6±1.0a 
 
0.46 ± 0.31 ab 
 
KEY: A= Control group, B= BPH group, C= PCa group, n= no of subjects, a= p < 0.05 when compared with group 
A; ab = p < 0.05 when compared with groups A and B; 
AIP = Atherogenic index of plasma 
Table 2 shows the mean levels of total cholesterol, high 
density lipoprotein-cholesterol, low density 
lipoprotein-cholesterol, very low density lipoprotein- 
cholesterol, Triacylglycerol and atherogenic index of 
plasma of the prostate cancer, BPH and control groups. 
The levels of the total cholesterol (5.8±1.7 mmol/l), 
low density lipoprotein- cholesterol (4.6±1.8mmol/l), 
very low density lipoprotein- cholesterol (0.7±0.5 
mmol/l) and Triacylglycerol (1.6±1.0 mmol/l) in 
prostate cancer group were significantly higher (p < 
0.05) compared to the levels obtained in the control 
group (4.4±0.9, 3.1±0.8, 0.4±0.1, 0.8±0.2; 
respectively). Similarly, in the BPH group, the mean 
levels of total cholesterol (5.7±1.3 mmol/l), low 
density lipoprotein (4.4±1.1 mmol/l), very low density 
lipoprotein (0.6±0.3 mmol/l) and Triacylglycerol  
(1.3±0.7 mmol/l) were significantly increased (p < 
0.05) compared to the control group. Although the 
levels of these lipid parameters were higher in the PCa 
group than in BPH group, the increase was not 
significant (p > 0.05). Conversely, the mean HDL 
levels were significantly lower (p < 0.05) in both BPH 
(0.7±0.2) and PCa (0.5±0.2) when compared to the 
values obtained for the control group (1.1±0.3) and the 
decrease was equally significant (p < 0.05) when the 
prostate cancer group was compared to the BPH group. 
The AIP of the PCa group (0.46 ± 0.31) was 
significantly higher (p < 0.05) than that of both BPH 
(0. 22 ± 0.24) and control group (- 0.11 ± 0.21); and 
also significantly higher (p < 0.05) when the values for 
BPH group was compared to that of the control group. 
Table 3: Correlation between total cholesterol, HDL-cholesterol, LDL-cholesterol, triacylglycerol 
testosterone, AIP and PSA in the BPH and Prostate cancer subjects. 
 
Parameter Control BPH PCa 
r p-value r p-value r p-value 
 
T.cholesterol 
 
 0.2496 
 
0.1684 
 
    -0.0622 
 
0.7354 
 
     0.4588 
 
0.0029** 
HDL-cholesterol    -0.0399 0.8283 0.0317 0.8632     -0.5721 0.0001** 
LDL-cholesterol   0.2738 0.1294   -0.1241 0.4985    0.4166 0.0075** 
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Triacylglycerol    0.1662 0.3632      0.1497 0.4135    0.2899 0.0696 
Testosterone   -0.0489 0.7905  0.4716 0.0064* 0.0319 0.8450 
AIP 0.125 0.495 0.132 0.471 0.532 0.000** 
     
* = a significant correlation at p < 0.05 levels; ** = significant correlation at p < 0.01 levels.  
T. cholesterol = Total cholesterol; r = Correlation coefficient 
 
The correlation between lipid parameters, testosterone 
and prostate specific antigen in the test and control 
subjects are shown in Table 3. In the PCa subjects, a 
significant positive correlation was observed between 
total cholesterol, LDL- cholesterol and PSA (r = 
0.4588, p =0. 0029, and r = 0.4166, p = 0.0075, 
respectively). Also there was a highly significant 
positive correlation existed between AIP and PSA (r = 
0.532, p = 0.000) in the PCa group. Conversely, a 
highly significant negative correlation was observed 
between prostate specific antigen and HDL- cholesterol 
(r = - 0.5721, p = 0. 0001) in the prostate cancer 
subjects. For the BPH patients, a significant positive 
correlation was also found between PSA and 
testosterone (r = 0.4716, p = 0.0064).  
 
Discussion 
Blood lipid levels as part of the metabolic syndrome 
are thought to be linked to cancer risk [1]. The mean 
total cholesterol, LDL and triacylglycerol were not 
only significantly higher in patients with prostate 
cancer compared to controls, but also showed a 
positive significant correlation with PSA indicating 
that as the prostate degenerates and the cancer 
progressed, their levels increased. Likewise we also 
noted that HDL was significantly lower in the PCa 
subjects compared to BPH and control subjects and 
that HDL levels were negatively correlated with PSA. 
This observation agrees with the finding of [23], who 
reported a positive association between increasing total 
cholesterol level and overall risk of prostate cancer 
particularly in the advanced stage of prostate cancer. It 
is also supports the work of [24] who observed that 
men with higher cholesterol had a significantly 
increased risk of developing high grade disease than 
men with a desirable cholesterol level and that 
modifying cholesterol may reduce incidence of more 
aggressive disease. Several underlying mechanisms by 
which cholesterol and prostate carcinogenesis may be 
linked have been proposed. These researchers 
suggested that Prostate cancer cells tend to over- 
accumulate cholesterol in their cell membrane, forming 
large lipid rafts which, in the cancer cells may facilitate 
pro-carcinogenic cell signaling [25-26; 23].  
Thus,having a lower cholesterol level may inhibit these 
pro-carcinogenic activities in the prostate cells. 
Similarly, this may be the same mechanism by which 
decreased HDL is associated with prostate cancer. 
Since HDL transports cholesterol from cells to the liver 
and other steroidogenic organs including the prostate 
thus removing harmful cholesterol from prostate tissue, 
thereby preventing the accumulation of cholesterol in 
the prostatic cell membranes [23], decreased HDL 
leads to the accumulation of cholesterol and formation 
lipid raft as stated above. Inflammation-related changes 
to HDL particles not only lower HDL cholesterol 
levels but also alter the anti-oxidant properties of HDL. 
It is thought that the lowering of HDL-cholesterol 
levels during inflammation is due to a reduction in 
cholesterol uptake by cells and an increase in their 
catabolism [27]. HDL inhibits oxidation and 
inflammation - properties which may also reduce 
prostate cancer risk [23]. However, our study differs 
from the findings of [28] which showed HDL did not 
cause any net change in the cholesterol content of the 
three prostate cancer cell lines examined, but rather 
induced the proliferation of androgen-independent 
prostate cancer cells. This may be because of the 
ability of HDL to also donate cholesterol to cells and 
the ability of cells to compensate for any loss of 
cholesterol by de novo synthesis [25].  
A significant increase was also observed for 
triacylglycerol in this study between PCa and control 
group. This observation agrees with the finding of [29] 
who stated that high triacylglycerol levels correlated 
well with a higher incidence of prostate cancer and also 
more especially with aggressive PCa. They suggested 
that high triacylglycerol levels in elderly patients may 
provide the basis for developing prostate cancer with 
worse outcomes. Likewise, [30] observed high 
triacylglycerol concentrations among subjects with 
lung, thyroid and rectal cancer. The potential 
mechanisms for the association between 
hypertriglyceridemia and cancer development include 
infection, inflammation, and oxidative stress [27][31], 
although the contribution of chronic stress caused by 
 Asian Pac. J. Health Sci., 2015; 2(2): 48-55                                             e-ISSN: 2349-0659,   p-ISSN: 2350-0964                         
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________
Duru et al     ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2015; 2(2): 48-55 
www.apjhs.com      53 
 
high triacylglycerol levels to prostate cancer 
development remains controversial [30]. The exact 
mechanisms by which lipids and lipoproteins may 
contribute to carcinogenesis are not clearly understood. 
Some studies suggest that LDL-cholesterol being more 
susceptible to oxidation in various pathologic 
conditions, generates higher lipid peroxidation during 
oxidative stress.The increased LDL-cholesterol 
observed in our study agrees with the findings of [32] 
who noted that LDL levels tend to be elevated in PCa 
due to its enhanced susceptibility to oxidation in 
prostatic cancer cells. Cholesterol-lowering treatment 
has been suggested to delay progression of prostate 
cancer by decreasing serum LDL [33]. Other 
researchers also have reported that higher LDL can 
increase the risk for some cancers, with the hormone-
related cancers in men and women being especially 
affected [23][1]. Cholesterol availability is likely an 
important prerequisite for prostate cancer growth since 
reducing cholesterol levels was reported to have 
retarded prostate cancer growth in a prostate cancer 
xenograft model [34]. Some researchers have observed 
improved recurrence-free survival after radical 
treatment of prostate cancer among men using 
cholesterol-lowering statin drugs [35] while others 
noted that the use of statins after prostate cancer 
diagnosis was associated with a decreased risk in 
prostate cancer mortality [36]. Determining the plasma 
levels of cholesterol and its sub-fraction could also be 
used as biomarkers for prostate cancer since lowering 
cholesterol levels might be a good strategy to prevent 
and delay prostate cancer progression and reduce 
prostate cancer mortality. However, we observed no 
difference in the lipid levels between prostate cancer 
and BPH subjects. Although PCa is one of the leading 
causes of death in men, approximately half of the men 
with PCa die of non-cancer-related etiology. Co 
morbid conditions are common in this group, but a 
particularly strong association has been noted between 
the presence of cardiovascular disease and the eventual 
cause of death [15]. Atherogenic index of plasma, 
measured as the logarithmically transformed ratio of 
the serum triglyceride to HDL-cholesterol, may reflect 
the actual composition of the lipoprotein spectrum that 
might predict both the cardiovascular risk and 
effectiveness of therapy especially in cardiovascular 
disorders [37].This index has been shown to be a 
highly significant independent predictor of myocardial 
infarction, even stronger than TC/HDL-cholesterol and 
LDL-cholesterol/HDL-cholesterol ratios. AIP, a new 
marker of atherogenicity, is directly related to the risk 
of atherosclerosis hence people with high AIP have a 
higher risk of coronary heart disease than those with 
low AIP [9]. It has been reported that AIP has higher 
predicted value for atherosclerosis as compared to 
individual pro atherogenic markers alone [37]. In the 
this study, the AIP value for PCa patients was higher 
than those of BPH and the controls and this correlated 
positively with PSA indicating a higher risk for 
cardiovascular disease, while patients, with BPH 
showed medium risk. Considering the fact that AIP 
values from negative ones to 0.15 is "safe” from the 
aspect of atherogenicity [10], these findings indicate 
that AIP which reflects the plasma lipoprotein profile 
can be an objective indicator of the atherogenic risk in 
patients with prostate diseases. The present study also 
indicates that prostate cancer subjects have reduced 
testosterone levels compared to BPH and control 
subjects. Although the levels of total testosterone were 
low there was no correlation between prostate specific 
antigen and testosterone levels. This agrees with [38] 
who reported that serum testosterone levels were 
significantly lower in patients with prostate cancer than 
in the controls. Similarly, Morgentaler et al [39] found 
no correlation between endogenous testosterone 
concentrations and serum PSA levels in prostate cancer 
patients. They concluded that variation in endogenous 
testosterone concentration does not appear to influence 
PSA levels. Earlier prospective study by [40] that 
analysed the hormone levels of a cohort of patients 
followed for 15 years before they developed benign 
prostatic hyperplasia or prostate cancer, no significant 
association was found between serum testosterone 
levels and PSA levels. According to [41], this could be 
attributed to a possible inhibition of testosterone 
production by PSA, resulting in a low serum level of 
the hormone. On the other hand García-Cruz et al [42] 
observed that low testosterone levels were related to 
higher prostate-specific antigen and higher tumour 
burden. A possible explanation for this relationship is 
that high-grade tumors are more aggressive and may be 
more androgen-independent than low-grade tumors, 
thereby continuing to progress despite the relative lack 
of testosterone [43]. Therefore, low testosterone levels 
might be an indicator of prostate cancer and not 
necessarily a cause. Previous studies suggest that low 
testosterone levels are associated with higher risk of 
cardiovascular and overall mortality. According to [44] 
low testosterone level in middle-aged Japanese men 
was found to be an independent risk factor for 
cardiovascular disease while [45] reported that lower 
testosterone levels were also correlated with elevated 
levels of total cholesterol, LDL-cholesterol and 
triacylglycerol. However, we did not find any 
relationship between the lipid parameters and 
testosterone levels of the prostate cancer subjects in the 
current study. 
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Conclusion 
 
In conclusion, our findings indicate that Nigerian men 
with prostate cancer and BPH have abnormal lipid 
profile and may have increased risk of cardiovascular 
diseases. AIP may serve as a veritable tool in 
predicting the high risk of cardiovascular diseases in 
prostate cancer patients and to a lesser extent in BPH. 
Prostate cancer patients have decreased levels of 
testosterone hormone but this is not correlated with 
PSA or the atherogenic lipid markers. 
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